ArticleCureus2026
Fatal Late-Onset Ornithine Transcarbamylase Deficiency in an Adolescent: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The late-onset phenotype represents the most prevalent form of ornithine transcarbamylase (OTC) deficiency and is characterized by marked clinical heterogeneity, with disease onset ranging from early infancy to adulthood. We describe the case of a 12-year-old female with no significant past medical history who presented to the Emergency Department with an impaired level of consciousness and profound hyperammonemia (plasma ammonia: 432 μg/dL, and impairment of consciousness). Despite early initiation of continuous renal replacement therapy and aggressive management of cerebral edema, the patient developed refractory neurological deterioration and died five days after presentation. This case highlights that the late-onset form of OTC deficiency may manifest with severe neurological involvement and may be life-threatening. Timely recognition and aggressive management of hyperammonemia and impending hyperammonemic coma are essential to achieve improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.